mycophenylate mofetil

PreclinicalSmall molecule

MMasonic Cancer Center, University of Minnesota

mycophenylate mofetil is one of 3 small molecule programs targeting Hematological Diseases. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hematological DiseasesRecruiting

Hematological DiseasesPreclinical

Recruiting

Competition

Competitive Landscape

2 competitors in Hematological Diseases

#DrugCompanyPhaseTrials

Cyclosporine a

Novartis

Preclinical

1 2

Umbilical Cord Blood

MMasonic Cancer Center, University of Minnesota

Preclinical

1 3

mycophenylate mofetil

MMasonic Cancer Center, University of Minnesota

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

N/ARecruiting

Hematological Diseases

NCT01962636

Clinical

Trials by Indication[1]

Renal Transplantation1 trial

RituxiMab INDuction in Renal Transplantation

Unknown status·GGuy's and St Thomas' NHS Foundation Trust·Phase 4·NCT01095172·100 enrolled

High Risk1 trial

HSCT for High Risk Inherited Inborn Errors

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00383448·38 enrolled

Hematological Diseases1 trial

Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases

Recruiting·MMasonic Cancer Center, University of Minnesota·N/A·NCT01962636·200 enrolled

Prevention1 trial

Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD

Completed·SStanford University·Phase 2·NCT00186628·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for mycophenylate mofetil. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — mycophenylate mofetil compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for mycophenylate mofetil. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Masonic Cancer Center, University of Minnesota company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MMasonic Cancer Center, University of Minnesota

mycophenylate mofetil

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Renal Transplantation1 trial

High Risk1 trial

Hematological Diseases1 trial

Prevention1 trial

References

Drug Info

Quick Facts

Related News